keyword
MENU ▼
Read by QxMD icon Read
search

bivalacqua

keyword
https://www.readbyqxmd.com/read/29432873/characterization-of-urothelial-cancer-circulating-tumor-cells-with-a-novel-selection-free-method
#1
Heather J Chalfin, Max Kates, Emma E van der Toom, Stephanie Glavaris, James E Verdone, Noah M Hahn, Kenneth J Pienta, Trinity J Bivalacqua, Michael A Gorin
OBJECTIVE: To investigate circulating tumor cells (CTCs) as biomarkers of urothelial carcinoma (UC). The majority of this work to date has utilized the CellSearch test, which has limited sensitivity due to reliance on positive selection for the cell surface protein EpCAM. We used a novel selection-free method to enumerate and characterize CTCs across a range of UC stages. MATERIALS AND METHODS: Blood samples from 38 patients (9 controls, 8 non-muscle invasive bladder cancer [NMIBC], 12 muscle-invasive bladder cancer [MIBC] and 9 metastatic UC) were processed with the AccuCyte-CyteFinder system...
February 9, 2018: Urology
https://www.readbyqxmd.com/read/29394072/molecular-profile-of-priapism-associated-with-low-nitric-oxide-bioavailability
#2
Justin D La Favor, Zongming Fu, Vidya Venkatraman, Trinity J Bivalacqua, Jennifer E Van Eyk, Arthur L Burnett
Priapism is a disorder in which prolonged penile erection persists uncontrollably, potentially leading to tissue damage. Priapism commonly afflicts patient populations with severely low nitric oxide (NO) bioavailability. As NO is a primary mediator of erection, the molecular mechanisms involved in priapism pathophysiology associated with low NO bioavailability are not well understood. The objective of this study was to identify dysregulated molecular targets and signaling pathways in penile tissue of a mouse model of low NO bioavailability that have potential relevance to priapism...
February 2, 2018: Journal of Proteome Research
https://www.readbyqxmd.com/read/29371143/surgical-factors-associated-with-male-and-female-sexual-dysfunction-after-radical-cystectomy-what-do-we-know-and-how-can-we-improve-outcomes
#3
REVIEW
Filippo Pederzoli, Jeffrey D Campbell, Hotaka Matsui, Nikolai A Sopko, Trinity J Bivalacqua
BACKGROUND: Sexual dysfunction after radical cystectomy (RC) is a frequent, though commonly overlooked symptom for both men and women. Improved oncological outcomes and the rising number of bladder cancer survivors mandate physicians to closely address and evaluate post-surgical sexual dysfunction and offer goal-directed treatment. Improvements in RC surgical techniques that promote post-operative sexual function have been proposed, alongside new quality-of-life inventories and sexual function therapeutic options; however, rigorous studies in the field are lacking...
January 19, 2018: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/29329894/neoadjuvant-dose-dense-mvac-versus-gc-in-patients-with-ct3-4an0m0-bladder-cancer-treated-with-radical-cystectomy
#4
Homayoun Zargar, Jay B Shah, Bas W van Rhijn, Siamak Daneshmand, Trinity J Bivalacqua, Philippe E Spiess, Peter C Black, Wassim Kassouf
BACKGROUND: Level I evidence supports the utility of neoadjuvant cisplatin-based chemotherapy (NAC) for muscle invasive bladder cancer (BCa). Since dose dense (ddMVAC) has mostly replaced traditional MVAC, we aimed to compare pathological response and survival rates in patients with locally advanced BCa receiving NAC with ddMVAC versus GC. METHODS: We retrospectively reviewed records of patients with urothelial cancer who received NAC and underwent cystectomy at 20 contributing institutions from 2000-2015...
January 9, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29307680/comparison-of-pathologic-stage-in-patients-treated-with-and-without-neoadjuvant-chemotherapy-for-high-risk-upper-tract-urothelial-carcinoma
#5
Ross S Liao, Mohit Gupta, Zeyad R Schwen, Hiten D Patel, Max Kates, Michael H Johnson, Noah M Hahn, David McConkey, Trinity J Bivalacqua, Phillip M Pierorazio
PURPOSE: High-risk upper tract urothelial carcinoma has been associated with poor survival outcomes. Limited retrospective data supports the use of neoadjuvant chemotherapy prior to radical nephroureterectomy. We evaluated differences in pathologic stage distribution in patients with high-risk upper tract urothelial carcinoma based on the use of neoadjuvant chemotherapy before radical nephroureterectomy to validate prior findings. MATERIALS AND METHODS: We performed a retrospective analysis of 240 patients at The Johns Hopkins Hospital from 2003-2017 with upper tract urothelial carcinoma...
January 4, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29288005/ex-vivo-culture-of-tumor-cells-from-n-methyl-n-nitrosourea-induced-bladder-cancer-in-rats-development-of-organoids-and-an-immortalized-cell-line
#6
Takahiro Yoshida, Max Kates, Nikolai A Sopko, Xiaopu Liu, Alok K Singh, William R Bishai, Gregory Joice, David J McConkey, Trinity J Bivalacqua
OBJECTIVE: We ex vivo cultured primary tumor cells from N-methyl-N-nitrosourea (MNU)-induced bladder tumors in rats and established an immortalized cell line from them. MATERIALS AND METHODS: Bladder tumors in rats were induced by instillation of MNU into the murine bladder. Primary tumor cells were prepared by the cancer-tissue originated spheroid method. An immortalized cell line was established by co-culture with fibroblasts. The cultured tumor cells were molecularly and functionally characterized by quantitative real-time polymerase chain reaction, Western blot, growth assay, and transwell migration assay...
December 26, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29280463/cavernous-nerve-injury-by-radiation-therapy-may-potentiate-erectile-dysfunction-in-rats
#7
Javed Mahmood, Caroline Q Connors, Allen A Alexander, Radmila Pavlovic, Santanu Samanta, Sandrine Soman, Hotaka Matsui, Nikolai A Sopko, Trinity J Bivalacqua, Daniel Weinreich, Cheng-Ying Ho, John Eley, Amit Sawant, Isabel L Jackson, Zeljko Vujaskovic
PURPOSE/OBJECTIVES: Radiation-induced erectile-dysfunction (RiED) is one of the most common side effects of radiation therapy (RT) and significantly reduces the quality of life (QoL) of cancer patients. Approximately 50% of prostate cancer patients experience RiED within 3 to 5 years after completion of RT. A series of vascular, muscular, and neurogenic injuries after prostate RT lead to RiED; however, the precise role of RT-induced neurogenic injury in RiED has not been fully established...
November 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29203268/efficacy-and-safety-of-blue-light-flexible-cystoscopy-with-hexaminolevulinate-hal-in-the-surveillance-of-bladder-cancer-a-phase-iii-comparative-multi-center-study
#8
Siamak Daneshmand, Sanjay Patel, Yair Lotan, Kamal Pohar, Edouard Trabulsi, Michael Woods, Tracy Downs, William Huang, Jeffrey Jones, Michael O'Donnell, Trinity Bivalacqua, Joel DeCastro, Gary Steinberg, Ashish Kamat, Matthew Resnick, Badrinath Konety, Mark Schoenberg, J Stephen Jones, Soroush Bazargani, Michael Cookson, Brian Cross, Costas Dan Lallas, Hoorman Djaladat, Leonard Gomella, Michael Johnson, James McKiernan, Mark Mann, Megan Merrill, Matthew Nielsen, Phillip Pierorazio, Raj Pruthi, Alexander Sankin, Anne Schuckman, Ahmad Shabsigh, Jay B Shah, Angela Smith, Kelley Stratton, Jennifer Taylor, Christopher Weight, Sven Wenske
PURPOSE: To compare blue light flexible cystoscopy (BLFC) with white light flexible cystoscopy (WLFC) in the detection of bladder cancer during surveillance. MATERIALS AND METHODS: Patients at high risk of recurrence received intravesical HAL before WLFC and randomization to BLFC. All suspicious lesions were documented. Patients with suspicious lesions were referred to the operating room (OR) for repeat WLC (white light) and BLC (blue light) cystoscopy. All suspected lesions underwent biopsy or resection and specimens were examined by an independent pathology consensus panel...
December 1, 2017: Journal of Urology
https://www.readbyqxmd.com/read/29152553/oncological-outcomes-of-sequential-intravesical-gemcitabine-and-docetaxel-in-patients-with-non-muscle-invasive-bladder-cancer
#9
Niv Milbar, Max Kates, Meera R Chappidi, Filippo Pederzoli, Takahiro Yoshida, Alexander Sankin, Phillip M Pierorazio, Mark P Schoenberg, Trinity J Bivalacqua
Background: Bacillus Calmette-Guérin (BCG) unresponsive/relapsing patients with non-muscle invasive bladder cancer (NMIBC) who prefer bladder preservation over radical cystectomy (RC) or those who do not qualify for surgery may be offered intravesical therapies. Gemcitabine (GEM) combined with Docetaxel (DOCE) has been offered at Johns Hopkins Hospital (JHH). Objective: To evaluate experience with GEM/DOCE, to confirm safety of the regimen, to identify populations that may benefit most, and to consider the appropriate endpoints for judging efficacy of second line therapies...
October 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/29113841/immunotherapy-with-checkpoint-blockade-in-the-treatment-of-urothelial-carcinoma
#10
REVIEW
Arlene O Siefker-Radtke, Andrea B Apolo, Trinity J Bivalacqua, Philippe E Spiess, Peter C Black
PURPOSE: Although immunotherapy has a long history in the treatment of urothelial carcinoma, its use was limited to intravesical therapy for non-muscle-invasive disease. The development of immune checkpoint blockers for systemic delivery has expanded the application of immunotherapy to advanced metastatic urothelial cancers. MATERIALS AND METHODS: The PubMed database was searched for publications regarding immune checkpoint blockers for the treatment of patients with urothelial carcinoma...
November 4, 2017: Journal of Urology
https://www.readbyqxmd.com/read/29067547/low-levels-of-psma-expression-limit-the-utility-of-18-f-dcfpyl-pet-ct-for-imaging-urothelial-carcinoma
#11
Scott P Campbell, Alexander S Baras, Mark W Ball, Max Kates, Noah M Hahn, Trinity J Bivalacqua, Michael H Johnson, Martin G Pomper, Mohamad E Allaf, Steven P Rowe, Michael A Gorin
OBJECTIVE: To explore the clinical utility of PSMA-targeted (18)F-DCFPyL PET/CT in patients with metastatic urothelial carcinoma. METHODS: Three patients with metastatic urothelial carcinoma were imaged with (18)F-DCFPyL PET/CT. All lesions with perceptible radiotracer uptake above background were considered positive. Maximum standardized uptake values were recorded for each detected lesion and findings on (18)F-DCFPyL PET/CT were compared to those on conventional imaging studies...
October 24, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/29066225/urinary-tissue-engineering-challenges-and-opportunities
#12
REVIEW
Anirudha Singh, Trinity J Bivalacqua, Nikolai Sopko
INTRODUCTION: In this review, we discuss major advancements and common challenges in constructing and regenerating a neo-urinary conduit (NUC). First, we focus on the need for regenerating the urothelium, the hallmark the urine barrier, unique to urinary tissues. Second, we focus on clinically feasible scaffolds based on decellularized matrices and molded collagen that are currently of great research interest. AIM: To discuss the major advancements in constructing a tissue-engineered NUC (TE-NUC) and the challenges involved in their successful clinical translation...
October 21, 2017: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/29032237/hospital-charges-and-length-of-stay-following-radical-cystectomy-in-the-enhanced-recovery-after-surgery-era
#13
Alice Semerjian, Niv Milbar, Max Kates, Michael A Gorin, Hiten D Patel, Heather J Chalfin, Steven M Frank, Christopher L Wu, William W Yang, Deb Hobson, Lindsay Robertson, Elizabeth Wick, Mark P Schoenberg, Phillip M Pierorazio, Michael H Johnson, C J Stimson, Trinity J Bivalacqua
OBJECTIVE: To report our center's experience with enhanced recovery after surgery (ERAS) pathway for radical cystectomy (RC), specifically evaluating complications, LOS, 30- and 90-day readmissions, and hospital charges. Pathways of this type have been shown to decrease the length of stay (LOS) and postoperative ileus. However, concerns persist that ERAS is costly and increases readmissions. To date, limited studies have evaluated these concerns. MATERIALS AND METHODS: Our ERAS protocol was implemented for RC in December 2015...
January 2018: Urology
https://www.readbyqxmd.com/read/28834453/intravesical-rad-ifn%C3%AE-syn3-for-patients-with-high-grade-bacillus-calmette-guerin-refractory-or-relapsed-non-muscle-invasive-bladder-cancer-a-phase-ii-randomized-study
#14
RANDOMIZED CONTROLLED TRIAL
Neal D Shore, Stephen A Boorjian, Daniel J Canter, Kenneth Ogan, Lawrence I Karsh, Tracy M Downs, Leonard G Gomella, Ashish M Kamat, Yair Lotan, Robert S Svatek, Trinity J Bivalacqua, Robert L Grubb, Tracey L Krupski, Seth P Lerner, Michael E Woods, Brant A Inman, Matthew I Milowsky, Alan Boyd, F Peter Treasure, Gillian Gregory, David G Sawutz, Seppo Yla-Herttuala, Nigel R Parker, Colin P N Dinney
Purpose Many patients with high-risk non-muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse. We assessed the efficacy and safety of recombinant adenovirus interferon alfa with Syn3 (rAd-IFNα/Syn3), a replication-deficient recombinant adenovirus gene transfer vector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC. Methods In this open-label, multicenter (n = 13), parallel-arm, phase II study ( ClinicalTrials...
October 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28808039/preclinical-evaluation-of-intravesical-cisplatin-nanoparticles-for-non-muscle-invasive-bladder-cancer
#15
Max Kates, Abhijit Date, Takahiro Yoshida, Umara Afzal, Pranjali Kanvinde, Taarika Babu, Nikolai A Sopko, Hotaka Matsui, Noah M Hahn, David J McConkey, Alexander Baras, Justin Hanes, Laura Ensign, Trinity J Bivalacqua
Purpose: Prior clinical trials evaluating cisplatin for non-muscle-invasive bladder cancer (NMIBC) were stopped due to local and systemic toxicity. Currently, there is still a need for improved intravesical therapies, and nanoparticle-based CDDP may be efficacious without the toxicity of free cisplatin observed in the past.Experimental Design: Cisplatin nanoparticles (CDDP NPs) were developed using biocompatible poly(l-aspartic acid sodium salt; PAA), both with and without low and high grafting density of methoxy-polyethylene glycol (PEG)...
August 14, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28736318/prostate-specific-membrane-antigen-targeted-18f-dcfpyl-positron-emission-tomography-computerized-tomography-for-the-preoperative-staging-of-high-risk-prostate-cancer-results-of-a-prospective-phase-ii-single-center-study
#16
Michael A Gorin, Steven P Rowe, Hiten D Patel, Igor Vidal, Margarita Mana-Ay, Mehrbod S Javadi, Lilja B Solnes, Ashley E Ross, Edward M Schaeffer, Trinity J Bivalacqua, Alan W Partin, Kenneth J Pienta, Zsolt Szabo, Angelo M De Marzo, Martin G Pomper, Mohamad E Allaf
PURPOSE: We prospectively evaluated the diagnostic performance of prostate specific membrane antigen targeted 18F-DCFPyL positron emission tomography/computerized tomography in the preoperative staging of men at high risk for harboring metastatic prostate cancer despite a negative conventional staging evaluation. MATERIALS AND METHODS: Men with clinically localized high or very high risk prostate cancer were imaged with 18F-DCFPyL positron emission tomography/computerized tomography before undergoing radical prostatectomy with standardized pelvic lymph node dissection...
July 20, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28709874/analysis-of-hospital-readmissions-after-prosthetic-urologic-surgery-in-the-united-states-nationally-representative-estimates-of-causes-costs-and-predictive-factors
#17
Filippo Pederzoli, Meera R Chappidi, Sarah Collica, Max Kates, Gregory A Joice, Nikolai A Sopko, Francesco Montorsi, Andrea Salonia, Trinity J Bivalacqua
BACKGROUND: The surgical treatment of urinary incontinence and erectile dysfunction by prosthetic devices has become part of urologic practice, although sparse data exist at a national level on readmissions and hospital costs. AIM: To assess causes and costs of early (≤30 days) and late (31-90 days) readmissions after implantation of penile prostheses (PPs), artificial urinary sphincters (AUSs), or PP + AUS. METHODS: Using the 2013 and 2014 US Nationwide Readmission Databases, sociodemographic characteristics, hospital costs, and causes of readmission were compared among PP, AUS and AUS + PP surgeries...
August 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28597078/spectrum-of-genetic-mutations-in-de-novo-punlmp-of-the-urinary-bladder
#18
Maria Del Carmen Rodriguez Pena, Aline C Tregnago, Marie-Lisa Eich, Simeon Springer, Yuxuan Wang, Diana Taheri, Dilek Ertoy, Kazutoshi Fujita, Stephania M Bezerra, Isabela W Cunha, Maria Rosaria Raspollini, Lijia Yu, Trinity J Bivalacqua, Nickolas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein, George J Netto
Our group and others have previously demonstrated the presence of TERT promoter mutations (TERT-mut) in 60-80% of urothelial carcinomas and some of their histologic variants. Five other genes have been frequently implicated in bladder cancer: FGRF3, TP53, PIK3CA, HRAS, and CDKN2A. In the current study, we sought to determine the prevalence of mutations in TERT and these five other genes in de novo papillary urothelial neoplasms of low malignant potential (PUNLMP) of the urinary bladder. A retrospective search of our archives for PUNLMP was performed and 30 de novo cases were identified and included in the study...
June 8, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28588015/intravesical-bcg-induces-cd4-t-cell-expansion-in-an-immune-competent-model-of-bladder-cancer
#19
Max Kates, Thomas Nirschl, Nikolai A Sopko, Hotaka Matsui, Christina M Kochel, Leonardo O Reis, George J Netto, Mohammad Hoque, Noah M Hahn, David J McConkey, Alex S Baras, Charles G Drake, Trinity J Bivalacqua
Intravesical bacillus Calmette-Guérin (BCG) immunotherapy is the standard of care in treating non-muscle-invasive bladder cancer, yet its mechanism of action remains elusive. Both innate and adaptive immune responses have been implicated in BCG activity. Although prior research has indirectly demonstrated the importance of T cells and shown a rise in CD4(+) T cells in bladder tissue after BCG, T-cell subpopulations have not been fully characterized. We investigated the relationship between effector and regulatory T cells in an immune competent, clinically relevant rodent model of bladder cancer...
July 2017: Cancer Immunology Research
https://www.readbyqxmd.com/read/28553331/rhoa-rock-activation-in-major-pelvic-ganglion-mediates-caspase-3-dependent-nitrergic-neuronal-apoptosis-following-cavernous-nerve-injury
#20
Michael Bell, Nikolai A Sopko, Hotaka Matsui, Johanna L Hannan, Trinity J Bivalacqua
No abstract text is available yet for this article.
April 2017: Neural Regeneration Research
keyword
keyword
35674
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"